Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

NCT04929392 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Esophageal Adenocarcinoma
Esophageal Squamous Cell Carcinoma
Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Interventions

DRUG: Carboplatin
PROCEDURE: Endoscopic Biopsy
RADIATION: External Beam Radiation Therapy
DRUG: Lenvatinib Mesylate
DRUG: Paclitaxel
BIOLOGICAL: Pembrolizumab
PROCEDURE: Resection

Sponsor

City of Hope Medical Center

Collaborators

[object Object]